

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of Hong et al.

Appln. No.: 09/512,019

Group Art Unit: 1652

Filed: February 24, 2000

Examiner: R., Hudson

Title: DNA Polymerase Having Ability to Reduce Innate Selective Discrimination

Against Fluorescent Dye-Labeled Dideoxynucleotides

October 25, 2001

## RESPONSE TO COMMUNICATION REGARDING SEQUENCE LISTING

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

Responsive to the Office Communication and Notice to Comply with Requirements of Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated September 28, 2001, please enter the attached paper copy of the sequence listing where appropriate. We also request that a copy of sequence listing in its computer readable form be transferred from parent application 09/157,397 (filed September 21, 1998).

In accordance with 37 CFR 1.821(f), it is submitted that the contents of the paper copy and the computer readable copy of the sequence listing from parent application 09/157,397 are the same. Neither the paper copy nor the computer readable copy includes new matter.

By:

Marlana Titus, Reg. No. 35,843

Tel. No. (301) 924-9600

Nash & Titus, LLC 3415 Brookeville Road, Suite 1000 Brookeville, Maryland 20833

	TRANSMITTAL LETTER (General - Patent Pending)	Docket No. Lee109						
In Re Application Of: H	long et al.							
Serial No.	Filing Date	Examiner	Group Art Unit					
09/ <b>§</b> 12,019	February 24, 2000	R. Hutson	1652					
JAN 0 8 2002 E	Having Ability to Reduce Innate eotides	Selective Discrimination Again	st Fluorescent					
TO THE ACCIOTANT COMMISSIONED FOR RATENTO								
TO THE ASSISTANT COMMISSIONER FOR PATENTS:								
Transmitted herewith is:								
	unication Regarding Sequence Lis ation Regarding Sequence Listing							
in the above identified application.								
☑ No additional fee i	s required.							
<ul> <li>□ A check in the amount of is attached.</li> <li>☑ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 500867 as described below. A duplicate copy of this sheet is enclosed.</li> </ul>								
	<ul><li>Charge the amount of</li><li>Credit any overpayment.</li></ul>							
•	ny additional fee required.							
Marlana Titus, Reg. No. 3: Nash & Titus, LLC	gnature 5,843	Dated: October 25, 2001						
3415 Brookeville Road								

**Suite 1000** Brookeville, MD 20833

(301) 924-9600

I certify that this document and fee is being deposited orOct. 25, 2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Marlana Titus

Typed or Printed Name of Person Mailing Correspondence



## UNITED STAT DEPARTMENT OF COMMERCE

**Patent and Trademark Office** 

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO.

09/512,019

02/24/00

HONG

G

LEE-109

HM22/0928

Pillsbury Madison & Sutro LLP Intellectual Property Group 1100 New York Avenue N W Ninth Floor

East Tower

Washington 00 2005-3918

EXAMINER

HUTSON, R

ART UNIT PAPER NUMBER

1652

-7 -

18.

DATE MAILED:

09/28/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Jul 128/01



09:58 30192456)3



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

ATTORNEY DOCKET NO.	APPLICANT	FIRST NAMED	FILING DATE	SERIAL NUMBER
		1	 - W	
EXAMINER				
PAPER NUMBER	ART UNIT			
2		•		
	DATE MAILED:	1		

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Any inquiry concerning this communication should be directed to Examiner Richard Hutson, Art Unit 1652, whose telephone number is (703) 308-0066.

Any inquiry of a general nature or relating to the status of this application should be directed to the Customer Service Center whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Richard Hutson, Ph.D. 9/24/2001

PRIMARY EXAMINER
GROUP 1800